Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy

Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy

PURPOSE: Immune checkpoint inhibitors (ICIs) have been successfully used in many clinical trials related to immunotherapy. This study aimed to investigate the clinical efficacy of ICIs and prognostic factors in patients with resectable non-small cell lung cancer (NSCLC) following neoadjuvant therapy...

Full description

Bibliographic Details
Main Authors: Gao, Z. (Author), Gong, J. (Author), Jiang, S. (Author), Liu, Z. (Author), Wang, X. (Author), Zhang, M. (Author), Zhang, Z. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
adverse event
cancer staging
Carcinoma, Non-Small-Cell Lung
human
Humans
immune checkpoint inhibitor
immunotherapy
Immunotherapy
Lung Neoplasms
lung tumor
neoadjuvant therapy
Neoadjuvant Therapy
Neoplasm Staging
non small cell lung cancer
non-small cell lung cancer
prognosis
Prognosis
prognostic factor
real-world effectiveness
retrospective study
treatment outcome
Treatment Outcome
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items